ARISEPT V LEChENII BOLEZNI AL'TsGEYMERA


Cite item

Full Text

Abstract

Представлены данные многочисленных исследований о применении Арисепта для лечения болезни Альцгеймера (БА) на стадии мягкой и умеренно выраженной деменции. Арисепт (донепезила гидрохлорид) - производное пиперидина, является высокоспецифичным обратимым ингибитором центральной ацетилхолинэстеразы, оказывает мягкое позитивное действие на эмоциональные и поведенческие симптомы у больных в дополнение к влиянию на когнитивные функции, хорошо переносится пациентами и не вызывает серьезных побочных эффектов. Результаты исследования эффективности и безопасности применения Арисепта, включившего 40 больных БА, хорошо согласуются с международным опытом использования этого препарата.

Full Text

Restricted Access

About the authors

S. I Gavrilova

References

  1. Davies P, Maloney A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2(8000):1403.
  2. Coyle J.T, Price D.L, DeLong M.R. Alzheimer's disease: a disorder of cortical chollnergic innervation. Science 1985;219:1184-90.
  3. Bartus R.T, Dean R.L, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
  4. Doraiswamy P.M. Current cholinergic therapy for symptoms of Alzheimer's disease. Primary Psychiatry 1996;3(11):3-11.
  5. Wilson A.L, Langley L.K, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory and safety. Pharmacol Biochem Behav 1995;51(2-3):509-14.
  6. Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-27.
  7. Mc Geer P.L. Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drug Aging 2000;17:1-11.
  8. Giacobini E. From molecular structure to Alzheimertherapy. Jpn J Pharmacol 1997;74:225-41.
  9. Drachman D, Leavitt J. Human memory and the cholinergic system: relationship to aging? Arch Neurol 1974;30:113-21.
  10. Sunderland T, Silver M.A. Neuroleptics and the treatment of dementia. Int J Geriatr Psychiatry 1988; 3:79-88.
  11. Forette F, Boller F. Drug development in Alzheimer's Disease. Ed. Gauthier S. Pharmacotherapy of Alzheimer's Disease. London: Martin Dunitz 1988:1-15.
  12. Yamanishi Y, Ogura H, Kosasa T, et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T., Fisher A., Yoshida M. (eds.): Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. New York: Plenum Press 1990;2:409-13.
  13. Rogers S.L, Friedhoff L.T, and Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebocontrolled trial. Dementia 1996;7:293-303.
  14. Feldman H, Geuthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living of patients with moderate to severe Alzheimer's disease and effect on caregiver burden. J Am Geriatr Soc 2003;51:737-44.
  15. Frolich L, Berger F, Calabrese P. Effect of donepezil on behavior and activities of daily living in clinical practice (abstract). Presented at Alzheimer's Disease and Related Disorders Association World Alzheimer Congress. 2000. Washington, DC.
  16. Weiner M.F, Martin-Cook K, Foster B.M, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry2000;61:487-92.
  17. Barak Y, Bodner E, Zemishlani H, et. al. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr 2001;33:237-41.
  18. Cummings J.L, Donohue J.A, Brooks R.L. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry2000;8:134-40.
  19. Clary C, McRae T, Griesing T, et al. The safety of donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease (abstract). Int J Neuropsyhopharmacol 2000;3(Suppl. l):S.267.
  20. Holmes G, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's disease. Neurology 2004;63:214-19.
  21. Жариков Г.А., Калын Я.Б., Колыхалов И.В. и др. Опыт применения арисепта (донепезила) в лечении болезни Альцгеймера. / В кн.: Болезнь Альцгеймера и старение. Материалы III Российской конференции. Под ред. С.И. Гавриловой. М., 2003. С. 76-87.
  22. Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2003.
  23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 146:939-44.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Bionika Media